Navigation Links
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
Date:9/8/2008

s of the study and it was not a major reason for discontinuation during the trial.

About liraglutide

Once-daily liraglutide is the first human Glucagon-Like Peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes. Liraglutide works by stimulating the release of insulin only when glucose levels become too high and by inhibiting appetite. On May 23, 2008, Novo Nordisk submitted a New Drug Application to the Food and Drug Administration in the US as well as a marketing authorization application to the European Medicines Agency in Europe, for the approval of liraglutide for the treatment of people with type 2 diabetes. A New Drug Application was also submitted for approval in Japan on July 15, 2008.

About LEAD(TM) (Liraglutide Effect and Action in Diabetes)

The LEAD(TM) program includes five randomized, controlled, double-blind phase 3a studies, involving about 4,000 people with type 2 diabetes in 40 countries.

Novo Nordisk is a healthcare company with an 85-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to economic success, environmental soundness, and social responsibility to employees and customers. With headquarters in Denmark, Novo Nordisk employs more than 26,000 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit novonordisk.com; for United States information, visit '/>"/>

SOURCE Novo Nordisk
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
4. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
8. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sept. 30, 2014 This study provides ... imaging informatics solutions including nuclear imaging informatics, PET ... The study assesses the size of the market ... 2013, and projects future growth based on the ... dynamics taking place in the broader markets for ...
(Date:9/30/2014)... 30, 2014  Decision Resources Group finds that the ... , China , India , ... strong rate through 2023. Dental implant procedure volumes will grow as ... rises. Other key findings from Decision Resources Group,s coverage ... , Dental implant penetration: Penetration of dental implants ...
(Date:9/30/2014)... 2014 A study using a relatively new ... look at the composition of carotid artery disease and ... treat the disease, a leading cause of stroke. ... between September 2010 and May 2012, was featured in ... the American College of Cardiology (JACC) Cardiovascular Interventions. ...
Breaking Medicine Technology:Analysis of the US Molecular Imaging Informatics Market 2Analysis of the US Molecular Imaging Informatics Market 3Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... 20, 2010 / PRNewswire-USNewswire/ -- As the season of ... to consider giving a simple gift that can make a ... initiative of the AMA Foundation that works with leading humanitarian ... in areas of need. Anyone can donate a new or ...
... 20, 2010 Each year, the Food and Drug ... wide variety of conditions and help consumers save money. ... for generic medications, go to http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm236544.htm . ... Consumer Updates at: https://service.govdelivery.com/service/subscribe.html?code=USFDA_9 . ...
Cached Medicine Technology:'Tis the Season to Give a Gift that Can Make a World of Difference 2
(Date:9/30/2014)... Centers (FQHCs) granted new patient appointments to Medicaid ... other primary care practices (non-FQHCs), in addition to ... a new 10-state University of Pennsylvania study published ... Using data from a previous "secret shopper" study ... that FQHCs community health clinics that receive ...
(Date:9/30/2014)... 30, 2014(BRONX, NY)Medications are the leading cause of allergy-related ... of death certificates from 1999 to 2010, conducted by ... Albert Einstein College of Medicine of Yeshiva University ... Journal of Allergy and Clinical Immunology , also found ... particularly high among older people and African-Americans and that ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Glycodrive ... Star Nutraceuticals designed to help maximize lean, strong muscle ... the body’s absorption of glucose has caught the attention ... “The main purpose behind Glycodrive is to help the ... muscle,” reports Michaels. “Carbs are essential in the muscle-building ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... certified nutrition specialist and best-selling author Mike Geary that is ... totally transform their body into a fat-burning machine in less ... prompting an investigative review. , “In our culture that ... can be hard to decipher what is really fact and ...
(Date:9/30/2014)... September 30, 2014 The American ... to help diabetics curb their sweet tooth, but the ... this September, suggests that zero-calorie sweeteners may actually ... diabetes. , The Weizmann Institute of Science in ... artificial sweeteners to mice, the mice developed glucose intolerance. ...
Breaking Medicine News(10 mins):Health News:Medicaid and Uninsured patients obtain new patient appointments most easily at FQHCs 2Health News:Comprehensive Study of allergic deaths in US finds medications are main culprit 2Health News:Glycodrive Review Exposes Blue Star Nutraceutical’s Supplement for Leaner, Stronger Muscles 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 2Health News:Fat Burning Kitchen: Review Exposes Mike Geary’s 24-Hour Diet Transformation for Helping the Body Burn Fat Through a Natural Diet 3Health News:Artificial Sweeteners May be Linked to Greater Diabetes Risk 2
... has mutated since 2002 to become more dangerous //and increases ... Asian strain H5N1 influenza virus has changed its characters since ... the virus multiplies in the ducks without infecting them but ... is a natural host for H5N1 influenza virus, these ducks ...
... on findings of a recent study researchers from Sweden ... stent is associated with coronary vasoconstriction in areas adjacent ... bare metal stents. ,Sirolimus-eluting stents are widely ... long-term clinical and angiographic outcome, however, recent concerns have ...
... often come to this side of the content //to get ... own countries. ,More and more Globetrotters are making a ... monsoons. Why you may ask? Well it’s believed strongly that ... in the rainy months of June, July and August. ...
... study by investigators from Sahlgrenska University Hospital in Gothenburg, ... outcomes of the health condition called drug-induced liver disease. ... Although stops when the medication is withdrawn, some effects ... can be fatal. An observation made by Dr. Hyman ...
... jail was detected as HIV positive //and admitted to a government ... Jail here, was diagnosed as HIV positive at the Patna Medical ... in a Bihar prison., ,The woman from a village in ... murder charge, has "almost" full blown AIDS, said M.P. Singh, who ...
... farm animals and spread in humans// by inhaling spores from infected ... taken. Now a report of Anthrax among the farm animals of ... disease among the health officials. ,Kerala has also imposed ban ... – a market town on the border of Kerala and Tamil ...
Cached Medicine News:Health News:Influenza Avian Flu strain has become more contagious and dangerous. , 2Health News:Influenza Avian Flu strain has become more contagious and dangerous. , 3Health News:Analyzing The Side Effects Of Sirolimus Stents 2Health News:Ayurvedic Therapies Cashing In On Medical Tourism 2Health News:Anthrax Scare In Tamil Nadu State of India 2
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
... introduces the Tag-It™ Cystic Fibrosis Kit, the ... genotyping. With validated performance criteria, this highly ... superior mutation coverage for carrier screening in ... in newborns. ,The Tag-It™ Cystic Fibrosis ...
Medicine Products: